XML 29 R23.htm IDEA: XBRL DOCUMENT v3.20.1
Fair Value Measurement (Tables)
 3 Months Ended
Mar. 31, 2020
Fair Value Disclosures [Abstract]  
Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis
The following tables present information about the above-referenced assets and liabilities and indicate the fair value hierarchy of the valuation techniques utilized to determine such fair value:
 
Fair Value Measurements as of March 31, 2020
 
Total
 
Quoted Prices in
Active Markets
for Identical
Assets
(Level 1)
 
Significant Other Observable Inputs
(Level 2)
 
Significant Unobservable Inputs
(Level 3)
Money market funds
$
2,517

 
$
2,517

 
$
—

 
$
—

Deferred compensation
(64,966
)
 
(64,966
)
 
—

 
—

Commercial paper
56,553

 
—

 
56,553

 
—

Acquisition contingent consideration liabilities
(3,300
)
 
—

 
—

 
(3,300
)

 
Fair Value Measurements as of December 31, 2019
 
Total
 
Quoted Prices in
Active Markets
for Identical
Assets
(Level 1)
 
Significant Other Observable Inputs
(Level 2)
 
Significant Unobservable Inputs
(Level 3)
Money market funds
$
2,508

 
$
2,508

 
$
—

 
$
—

Deferred compensation
(81,064
)
 
(81,064
)
 
—

 
—

Commercial paper
59,243

 
—

 
59,243

 
—

Acquisition contingent consideration liabilities
(23,100
)
 
—

 
—

 
(23,100
)
Reconciliations of Changes in the Fair Value of Contingent Consideration Liabilities
The following table sets forth a reconciliation of changes in the fair value of contingent consideration liabilities classified as Level 3 in the fair value hierarchy:
 
2020
 
2019
Balance as of January 1,
$
(23,100
)

$
(7,700
)
Settlement of Advanced contingent consideration liability for year ended December 31, 2019
20,000

 
—

Contingent consideration liability from Silversheet acquisition on January 30, 2019
—

 
(1,500
)
Change in fair value of contingent consideration liability from MedPartners acquisition
—

 
700

Change in fair value of contingent consideration liability from b4health acquisition
(200
)
 
—

Balance as of March 31,
$
(3,300
)
 
$
(8,500
)
Schedule of Fair Value of Financial Instruments See additional information in “Item 8. Financial Statements and Supplementary Data—Notes to Consolidated Financial Statements—Note (8), Notes Payable and Credit Agreement” of our 2019 Annual Report.
 
As of March 31, 2020
 
As of December 31, 2019
 
Carrying
Amount
Estimated
Fair Value
 
Carrying
Amount
Estimated
Fair Value
2024 Notes
$
325,000

$
312,000

 
$
325,000

$
337,188

2027 Notes
300,000

283,500

 
300,000

301,500